Mindray Medical International (NYSE: MR ) reported earnings on Aug. 6. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Mindray Medical International beat expectations on revenues and earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share grew significantly.
Gross margins increased, operating margins dropped, and net margins contracted.
Mindray Medical International chalked up revenue of $267.8 million. The five analysts polled by S&P Capital IQ expected revenue of $258.8 million on the same basis. GAAP reported sales were 23% higher than the prior-year quarter's $217.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.50. The five earnings estimates compiled by S&P Capital IQ predicted $0.47 per share. GAAP EPS of $0.44 for Q2 were 19% higher than the prior-year quarter's $0.37 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 57.4%, 40 basis points better than the prior-year quarter. Operating margin was 20.9%, 90 basis points worse than the prior-year quarter. Net margin was 19.4%, 120 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $264.8 million. On the bottom line, the average EPS estimate is $0.42.
Next year's average estimate for revenue is $1.06 billion. The average EPS estimate is $1.77.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,354 members out of 1,391 rating the stock outperform, and 37 members rating it underperform. Among 269 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 254 give Mindray Medical International a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mindray Medical International is outperform, with an average price target of $33.01.